{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:24:39Z","timestamp":1778502279543,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd011626","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000}}],"reference-count":89,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011626.pub2","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T05:46:36Z","timestamp":1531374396000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Alina","family":"Sadaf","sequence":"first","affiliation":[{"name":"University of Florida, Sacred Heart Children's Hospital; 6th Floor Nemours 5153 North 9th Avenue Pensacola Florida USA 32504"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babar","family":"Hasan","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital; Department of Paediatrics and Child Health; Stadium Road PO Box 3500 Karachi Sindh Pakistan 74800"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai K","family":"Das","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital; Division of Women and Child Health; Stadium Road PO Box 3500 Karachi Sind Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Colan","sequence":"additional","affiliation":[{"name":"Boston Children's Hospital; Department of Cardiology; 300 Longwood Avenue Bader, 2nd Floor Boston Massachusetts USA MA 02115"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najveen","family":"Alvi","sequence":"additional","affiliation":[{"name":"Aga Khan University; Department of Pediatrics; Stadium Road Karachi Pakistan 74800"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"10.1002\/14651858.CD011626.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.amjmed.2013.05.002","article-title":"Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial","volume":"126","author":"Fernandes","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011626.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2016-06-721183","article-title":"A randomised trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major","volume":"128","author":"Fernandes","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD011626.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"issue":"19","key":"10.1002\/14651858.CD011626.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2009-05-222729","article-title":"Deferasirox pharmacokinetics in patients with adequate versus inadequate response","volume":"114","author":"Chirnomas","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD011626.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2010.05.005","article-title":"Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone","volume":"45","author":"Lai","year":"2010","journal-title":"Blood Cells, Molecules and Diseases"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0006|cit6","unstructured":"NCT00115349 Combination therapy compared with single-drug therapy in patients with cardiac diseases clinicaltrials.gov\/ct2\/show\/NCT00115349"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0007|cit7","unstructured":"NCT00712738 Oral nifedipine to treat iron overload clinicaltrials.gov\/ct2\/show\/NCT00712738"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0008|cit8","unstructured":"NCT01927913 Treatment of iron overload requiring chelation therapy clinicaltrials.gov\/ct2\/show\/NCT01927913"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0009|cit9","unstructured":"NCT02173951 An algorithm to start iron chelation in minimally transfused young beta-thalassemia major patients clinicaltrials.gov\/ct2\/show\/NCT02173951"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0010|cit10","unstructured":"El-Haggar SM Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia www.clinicaltrials.gov"},{"issue":"14","key":"10.1002\/14651858.CD011626.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2011-10-386268","article-title":"A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload","volume":"119","author":"Neufeld","year":"2012","journal-title":"Blood"},{"issue":"S1","key":"10.1002\/14651858.CD011626.pub2-BIB0012|cit12","first-page":"848","article-title":"Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassemia major: a randomised control trial","volume":"101","author":"Alvi","year":"2016","journal-title":"Haematologica. Conference: 21st congress of the European Hematology Association. Denmark"},{"issue":"12","key":"10.1002\/14651858.CD011626.pub2-BIB0013|cit13","first-page":"e005360","article-title":"Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial","volume":"4","author":"Shakoor","year":"2014","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Shakoor A Zahoor M Sadaf A Alvi N Fadoo Z Rizvi A Effect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial BMJ Open 2014 e005360 10.1136\/bmjopen-2014-005360","DOI":"10.1136\/bmjopen-2014-005360"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0015|cit15","unstructured":"NCT02474420 Amlodipine as adjuvant treatment to iron chelation for prevention of cardiac iron overload in thalassemia patients (CANALI) clinicaltrials.gov\/ct2\/show\/NCT02474420"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1532-429X-14-8","article-title":"Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major","volume":"14","author":"Alpendurada","year":"2012","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0017|cit17","volume-title":"Community control of genetic and congenital disorders. Eastern Mediterranean region office technical publication series 24","author":"Alwan","year":"1997"},{"issue":"23","key":"10.1002\/14651858.CD011626.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload","volume":"22","author":"Anderson","year":"2001","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"Article ID: 727","DOI":"10.1155\/2013\/727905","article-title":"The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders","volume":"2013","author":"Angastiniotis","year":"2013","journal-title":"Scientific World Journal"},{"issue":"10","key":"10.1002\/14651858.CD011626.pub2-BIB0020|cit20","first-page":"1187","article-title":"Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD011626.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjh.12643","article-title":"Myocardial iron overload in thalassaemia major. How early to check?","volume":"164","author":"Borgna-Pignatti","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD011626.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0002-9343(71)90240-3","article-title":"Iron in the heart: etiology and clinical significance","volume":"51","author":"Buja","year":"1971","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMe020086","article-title":"Effect of consanguinity on screening for thalassemia","volume":"347","author":"Cao","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011626.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clinthera.2007.05.007","article-title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia","volume":"29","author":"Cappellini","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"14","key":"10.1002\/14651858.CD011626.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.110.007641","article-title":"On T2* magnetic resonance and cardiac iron","volume":"123","author":"Carpenter","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD011626.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00277-012-1480-8","article-title":"Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients","volume":"91","author":"Cassinerio","year":"2012","journal-title":"Annals of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD011626.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000171088","article-title":"Survival and complications of beta-thalassaemia in Lebanon: a decade\u2019s experience of centralized care","volume":"120","author":"Charafeddine","year":"2008","journal-title":"Acta Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD011626.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"19","key":"10.1002\/14651858.CD011626.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomised trials.","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011626.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0891-5849(02)00772-4","article-title":"Molecular bases of cellular iron toxicity","volume":"32","author":"Eaton","year":"2002","journal-title":"Free Radical Biology & Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011626.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0002-9149(93)90735-U","article-title":"Transient myocardial ischaemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol","volume":"71","author":"Egstrup","year":"1993","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011626.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues.","volume":"31","author":"Elbourne","year":"Feb 2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/01.CIR.30.5.698","article-title":"Late cardiac complications of chronic, severe, refractory anaemia with haemochromatosis","volume":"30","author":"Engle","year":"1964","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD011626.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/01.CIR.80.2.285","article-title":"Nifedipine potentiates cardiopulmonary baroreflex control of sympathetic nerve activity in healthy humans: direct evidence from microneurographic studies","volume":"80","author":"Ferguson","year":"1989","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD011626.pub2-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004450.pub3","article-title":"Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011626.pub2-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004839.pub3","article-title":"Oral deferiprone for iron chelation in people with thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011626.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0008-6363(99)00306-5","article-title":"Voltage-gated calcium-channels and antiarrhythmic drug action","volume":"45","author":"Grace","year":"2000","journal-title":"Cardiovascular Research"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations.","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD011626.pub2-BIB0039|cit39","first-page":"1185","article-title":"Treatment of hypertension with calcium antagonists. Review","volume":"5","author":"Guazzi","year":"1983","journal-title":"Hypertension"},{"issue":"13","key":"10.1002\/14651858.CD011626.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jacc.2010.03.083","article-title":"Iron overload cardiomyopathy: better understanding of an increasing disorder","volume":"56","author":"Gujja","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD011626.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2146\/ajhp110486","article-title":"Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics","volume":"69","author":"Henneman","year":"2012","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2010.05544.x","article-title":"Pathogenesis and management of iron toxicity in thalassaemia","volume":"1202","author":"Hershko","year":"2010","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"12","key":"10.1002\/14651858.CD011626.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2174\/0929867033457629","article-title":"Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload","volume":"10","author":"Hider","year":"2003","journal-title":"Current Medicinal Chemistry"},{"issue":"11","key":"10.1002\/14651858.CD011626.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD011626.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"29","key":"10.1002\/14651858.CD011626.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1002\/sim.3427","article-title":"Meta-analysis of skewed data: combining results reported on log-transformed or raw scales","volume":"27","author":"Higgins","year":"2008","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0047|cit47","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group editor(s) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011626.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/taap.1995.1008","article-title":"Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum","volume":"130","author":"Kim","year":"1995","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"20","key":"10.1002\/14651858.CD011626.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0050|cit50","first-page":"382","article-title":"Fibrosis in cardiac siderosis: update on historical perspectives","volume":"97 Suppl 1","author":"Kirk","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"10.1002\/14651858.CD011626.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1600-0609.2012.01779.x","article-title":"T-type calcium channel blockade improves survival and cardiovascular function in thalassaemic mice","volume":"88","author":"Kumfu","year":"2012","journal-title":"European Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD011626.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/01480545.2012.726625","article-title":"Ferric iron uptake into cardiomyocytes of \u03b2-thalassaemic mice is not through calcium channels","volume":"36","author":"Kumfu","year":"2013","journal-title":"Drug and Chemical Toxicology"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/asheducation-2011.1.451","article-title":"Real-world use of iron chelators","volume":"1","author":"Kwiatkowski","year":"2011","journal-title":"Hematology. American Society of Hematology, Education Program"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The\u00a0PRISMA\u00a0statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati\u00a0A","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD011626.pub2-BIB0055|cit55","first-page":"147","article-title":"Heart cells in culture: a model of myocardial iron overload and chelation","volume":"106","author":"Link","year":"1985","journal-title":"Journal of Laboratory and Clinical Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011626.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1182\/blood.V83.9.2692.bloodjournal8392692","article-title":"Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells","volume":"83","author":"Link","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD011626.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1067\/mlc.2001.116487","article-title":"Exploring the \u201ciron shuttle\u201d hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labelled iron stores and in iron-loaded rat heart cells in culture","volume":"138","author":"Link","year":"2001","journal-title":"Journal of Laboratory and Clinical Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011626.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/blood.V88.9.3608.bloodjournal8893608","article-title":"Oxidative stress and antioxidant status in beta-thalassaemia major: iron overload and depletion of lipid-soluble antioxidants","volume":"88","author":"Livrea","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD011626.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm1542","article-title":"Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1","volume":"13","author":"Ludwiczek","year":"2007","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011626.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23219","article-title":"Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients","volume":"87","author":"Maggio","year":"2012","journal-title":"American Journal of Hematology"},{"issue":"8","key":"10.1002\/14651858.CD011626.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007476.pub3","article-title":"Deferasirox for managing iron overload in people with thalassaemia","author":"Meerpohl","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9220","key":"10.1002\/14651858.CD011626.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011626.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00365510601046557","article-title":"Epidemiology of haemoglobin disorders in Europe: an overview","volume":"67","author":"Modell","year":"2007","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bulletin of the World Health Organization"},{"issue":"11","key":"10.1002\/14651858.CD011626.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.cardfail.2010.05.009","article-title":"Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment","volume":"16","author":"Murphy","year":"2010","journal-title":"Journal of Cardiac Failure"},{"issue":"9","key":"10.1002\/14651858.CD011626.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassaemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011626.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm920","article-title":"L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy","volume":"9","author":"Oudit","year":"2003","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011626.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00109-005-0029-x","article-title":"Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy","volume":"84","author":"Oudit","year":"2006","journal-title":"Journal of Molecular Medicine"},{"issue":"24","key":"10.1002\/14651858.CD011626.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011626.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/RMR.0000000000000011","article-title":"T2* imaging of the heart: methods, applications, and outcomes","volume":"23","author":"Baksi","year":"2014","journal-title":"Topics in Magnetic Resonance Imaging"},{"issue":"1","key":"10.1002\/14651858.CD011626.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1532-429X-15-1","article-title":"Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy","volume":"15","author":"Pepe","year":"2013","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"13","key":"10.1002\/14651858.CD011626.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2010-08-300335","article-title":"How I treat thalassemia","volume":"118","author":"Rachmilewitz","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0073|cit73","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"11","key":"10.1002\/14651858.CD011626.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMra050436","article-title":"Beta-thalassemia","volume":"353","author":"Rund","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1161\/01.HYP.11.3_Pt_2.II42","article-title":"Side effects of calcium channel blockers","volume":"11","author":"Russell","year":"1988","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0076|cit76","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 11: Presenting results and \u2018Summary of findings\u2019 tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjhyper.2005.11.003","article-title":"Interaction of grapefruit juice and calcium channel blockers","volume":"19","author":"Sica","year":"2006","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2125.1986.tb02860.x","article-title":"The mechanism of action of calcium antagonists relative to their clinical applications","volume":"21 Suppl 2","author":"Singh","year":"1986","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011626.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/01.RES.84.11.1302","article-title":"Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload","volume":"84","author":"Tsushima","year":"1999","journal-title":"Circulation Research"},{"issue":"9","key":"10.1002\/14651858.CD011626.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00277-012-1465-7","article-title":"A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births.","volume":"91","author":"Voskaridou","year":"Sept 2012","journal-title":"Annals of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD011626.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.mri.2009.12.001","article-title":"Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia","volume":"28","author":"Wang","year":"2010","journal-title":"Magnetic Resonance Imaging"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0082|cit82","first-page":"704","article-title":"Inherited haemoglobin disorders: an increasing global health problem","volume":"79","author":"Weatherall","year":"2001","journal-title":"Bulletin of the World Health Organization"},{"issue":"7","key":"10.1002\/14651858.CD011626.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0735-1097(97)00095-8","article-title":"Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics","volume":"29","author":"Wenzel","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD011626.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011626.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1934-6","DOI":"10.1182\/blood-2003-06-1919","article-title":"Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease","volume":"103","author":"Wood","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1196\/annals.1345.047","article-title":"Physiology and pathophysiology of iron cardiomyopathy in thalassaemia","volume":"1054","author":"Wood","year":"2005","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"6","key":"10.1002\/14651858.CD011626.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"917-20","DOI":"10.3324\/haematol.12513","article-title":"Onset of cardiac iron loading in pediatric patients with thalassemia major","volume":"93","author":"Wood","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"10.1002\/14651858.CD011626.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e82662","DOI":"10.1371\/journal.pone.0082662","article-title":"Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomised controlled trials","volume":"8","author":"Xia","year":"2013","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD011626.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/2193-1801-3-168","article-title":"Potential statin-drug interactions: prevalence and clinical significance","volume":"3","author":"Zhelyazkova-Savova","year":"2014","journal-title":"Springerplus"}],"updated-by":[{"DOI":"10.1002\/14651858.cd011626.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011626.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T08:47:28Z","timestamp":1672390048000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011626.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":89,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011626.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD011626.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,12]]}}}